| P50 | author | Manuela Grazina | Q48715212 |
| P2093 | author name string | Ramiro Barrantes | |
| | Adrián LLerena | |
| | Eva M Peñas-Lledó | |
| | Idania Rodeiro | |
| | Martha Sosa-Macías | |
| | Eduardo Tarazona-Santos | |
| | Enrique Terán | |
| | Marisol López-López | |
| | Luis R Calzadilla | |
| | Fernanda Rodrigues-Soares | |
| | Graciela E Moya | |
| | Francisco E Estévez-Carrizo | |
| | Ronald Ramírez-Roa | |
| | RIBEF Ibero-American Network of Pharmacogenetics and Pharmacogenomics | |
| P2860 | cites work | Population structure and eigenanalysis | Q21145248 |
| | A global reference for human genetic variation | Q25909434 |
| | Development of a Panel of Genome-Wide Ancestry Informative Markers to Study Admixture Throughout the Americas | Q28972484 |
| | Fast model-based estimation of ancestry in unrelated individuals | Q29614705 |
| | Human genome diversity: frequently asked questions | Q34115476 |
| | Socioeconomic and nutritional factors account for the association of gastric cancer with Amerindian ancestry in a Latin American admixed population | Q34368829 |
| | Comparing genetic ancestry and self-described race in african americans born in the United States and in Africa | Q36828761 |
| | Influence of CYP2C9 and VKORC1 on warfarin response during initiation of therapy | Q37463152 |
| | Interethnic variability of CYP2D6 alleles and of predicted and measured metabolic phenotypes across world populations. | Q38260323 |
| | Interethnic variation of CYP2C19 alleles, 'predicted' phenotypes and 'measured' metabolic phenotypes across world populations. | Q38616806 |
| | Worldwide interethnic variability and geographical distribution of CYP2C9 genotypes and phenotypes. | Q38643436 |
| | Pharmacogenetics and ethnicity: relevance for clinical implementation, clinical trials, pharmacovigilance and drug regulation in Latin America. | Q38803190 |
| | To Genotype or Phenotype for Personalized Medicine? CYP450 Drug Metabolizing Enzyme Genotype-Phenotype Concordance and Discordance in the Ecuadorian Population | Q39183846 |
| | Development of a pharmacogenetic-based warfarin dosing algorithm and its performance in Brazilian patients: highlighting the importance of population-specific calibration | Q40862073 |
| | QTc interval lengthening is related to CYP2D6 hydroxylation capacity and plasma concentration of thioridazine in patients | Q44263549 |
| | Relationship between risperidone and 9-hydroxy-risperidone plasma concentrations and CYP2D6 enzyme activity in psychiatric patients | Q44272336 |
| | CYP2C9 allele frequency differences between populations of Mexican-Mestizo, Mexican-Tepehuano, and Spaniards. | Q46221248 |
| | Pharmacogenetics of warfarin: development of a dosing algorithm for brazilian patients | Q46406579 |
| | Lessons from Cuba for Global Precision Medicine: CYP2D6 Genotype Is Not a Robust Predictor of CYP2D6 Ultrarapid Metabolism | Q47337181 |
| | Elevated CYP2C19 expression is associated with depressive symptoms and hippocampal homeostasis impairment | Q47368013 |
| | CYP450 Genotype/Phenotype Concordance in Mexican Amerindian Indigenous Populations-Where to from Here for Global Precision Medicine? | Q48033521 |
| | A combined high CYP2D6-CYP2C19 metabolic capacity is associated with the severity of suicide attempt as measured by objective circumstances. | Q48235443 |
| | CYP2D6 ultrarapid metabolism and early dropout from fluoxetine or amitriptyline monotherapy treatment in major depressive patients | Q48655811 |
| | High frequency of CYP2D6 ultrarapid metabolizer genotypes in an Ashkenazi Jewish population from Argentina. | Q53787657 |
| | Relevance of the ancestry for the variability of the Drug-Metabolizing Enzymes CYP2C9, CYP2C19 and CYP2D6 polymorphisms in a multiethnic Costa Rican population | Q56794510 |
| | Differential effects of predictors of warfarin dose according to race/color categories in the admixed Brazilian population | Q57163386 |
| | Neurological toxicity after phenytoin infusion in a pediatric patient with epilepsy: influence of CYP2C9, CYP2C19 and ABCB1 genetic polymorphisms | Q57585710 |
| | Standardized Biogeographic Grouping System for Annotating Populations in Pharmacogenetic Research | Q64120327 |
| | Admixture and ethno-specific alleles: missing links for global pharmacogenomics | Q88153428 |
| | CYP2C9*61, a rare missense variant identified in a Puerto Rican patient with low warfarin dose requirements | Q90284996 |
| | Interethnic Variability in CYP2D6, CYP2C9, and CYP2C19 Genes and Predicted Drug Metabolism Phenotypes Among 6060 Ibero- and Native Americans: RIBEF-CEIBA Consortium Report on Population Pharmacogenomics | Q91296228 |
| | The Missing Diversity in Human Genetic Studies | Q92555493 |
| P577 | publication date | 2019-08-02 | |
| P1433 | published in | Clinical Pharmacology & Therapeutics | Q1101529 |
| P1476 | title | Genomic Ancestry, CYP2D6, CYP2C9, and CYP2C19 Among Latin Americans | |